SCHEMBL21597748

SCHEMBL21597748

Cn1nc(-c2ncco2)cc1N

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
BRD4 O60885 2/20 0.36
CSNK1A1 P48729 1/20 0.34
CSNK1D P48730 1/20 0.34
CSNK1E P49674 1/20 0.34
ADORA2A P29274 3/20 0.34
ADORA1 P30542 2/20 0.33
TLR7 Q9NYK1 1/20 0.33
PDE1A P54750 1/20 0.33
PDE1B Q01064 1/20 0.33
PDE1C Q14123 1/20 0.33
ADORA2B P29275 1/20 0.33
CCNC P24863 2/20 0.33
CDK8 P49336 2/20 0.33
BACE1 P56817 5/20 0.32
BACE2 Q9Y5Z0 5/20 0.32
HPGD P15428 1/20 0.32
CFTR P13569 1/20 0.32
PDE10A Q9Y233 1/20 0.32
HPGDS O60760 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21241221 0.82 BRD4 (0.36) BRD4ADORA1TLR7PDE1APDE1B
SCHEMBL21604025 0.78 BRD4 (0.33) BRD4ADORA2APDE1APDE1BPDE1C
SCHEMBL22952445 0.78 BRD4 (0.33) BRD4CCNCCDK8BACE1BACE2
SCHEMBL21233192 0.78 PDE1A (0.34) BRD4ADORA2APDE1APDE1BPDE1C
SCHEMBL31412366 0.78 BRD4 (0.36) BRD4CSNK1A1CSNK1DCSNK1EADORA2A
SCHEMBL26638827 0.76 KDM4E (0.44) BRD4ADORA2A
SCHEMBL27415204 0.73 BRD4 (0.31) BRD4
SCHEMBL26638897 0.73 LMNA (0.45) HPGD
SCHEMBL26785868 0.72 ADORA2A (0.35) BRD4ADORA2APDE1APDE1BPDE1C
SCHEMBL15813458 0.71 TSHR (0.39) BACE1BACE2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2024-06-25 US disclosed
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE UCB Biopharma SRL (BE) 2022-10-20 US disclosed
EP-3810606-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2021-04-28 EP disclosed
CN-112566910-A Thiophene derivatives for the treatment of IgE induced diseases UCB生物制药有限责任公司 2021-03-26 CN disclosed
WO-2019243550-A1 THIOPHENE DERIVATIVES FOR THE TREATMENT OF DISORDERS CAUSED BY IGE UCB Biopharma SRL (BE) 2019-12-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220332709-A1 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 BRD4 1619/4885CSNK1A1 502/4885CSNK1D 704/4885
US-12018021-B2 Thiophene derivatives for the treatment of disorders caused by IgE TSLP, CYSLTR1, CYSLTR2 BRD4 1619/4885CSNK1A1 502/4885CSNK1D 704/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.